Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore undertook the NHL Subtypes Project, an international collaborative effort to investigate the etiologies of NHL subtypes. This article describes in detail the project rationale and design.
In 2001, the World Health Organization (WHO) introduced an international consensus-based classification for hematologic malignancies (2, 3) . This classification provided the first biologically based, integrated framework for consistently defining the subtypes of NHL, thereby greatly facilitating research on this heterogeneous group of diseases. Subsequent analyses of population-based registry data revealed striking differences in incidence among NHL subtypes by age, sex, race/ethnicity, and calendar year (11) (12) (13) (14) . Additionally, studies have reported that certain infectious agents are associated with risk of specific NHL subtypes, such as human T-cell lymphotropic virus, type I (HTLV-I) with adult T-cell leukemia/lymphoma (15) , and Helicobacter pylori with gastric mucosa-associated lymphoid tissue NHL (16) , whereas infection with the HIV (17) (18) (19) and hepatitis C virus (20, 21) are associated with multiple NHL subtypes. Variation in risk among NHL subtypes also is clearly evident for associations with autoimmune conditions (22) , iatrogenic immunodeficiency associated with solid organ transplantation (23) (24) (25) , and certain common genetic variants (26) (27) (28) (29) (30) (31) . In contrast, cumulative sun exposure appears to affect the risk of all NHL subtypes (32) .
The International Lymphoma Epidemiology Consortium (InterLymph) is an open scientific forum for epidemiological research in NHL (http://epi.grants.cancer.gov/InterLymph/) (33) . Formed in 2001, InterLymph's primary goal was to facilitate pooled analyses of individual-level data from lymphoid malignancy case-control studies with the purpose of increasing statistical power for examining associations with rare exposures and less common NHL subtypes. Collaborations among epidemiologists in Europe, North America, and Australia were initiated in the 1990s through formal (34) and informal meetings, where investigators shared draft protocols and questionnaires for recent and planned epidemiological studies. Since its official inception, InterLymph has expanded to become an interdisciplinary group of epidemiologists, pathologists, clinicians, geneticists, immunologists, and biostatisticians who have worked together to publish pooled analyses on a range of individual risk factors among NHL subtypes (20, 22, 27, 28, 32, (35) (36) (37) (38) (39) (40) (41) (42) . Despite advances in our understanding of NHL etiology, broad evaluation of risk factor profiles for specific NHL subtypes across a range of exposures is lacking, and little is known about risk factors for many of the less common NHL subtypes. We therefore undertook the "InterLymph NHL Subtypes Project," a consortium-wide initiative with the aims of 1) evaluating associations for medical history, family history of hematologic malignancy, lifestyle factors, and occupation with specified NHL subtypes, and 2) quantitatively assessing etiologic heterogeneity among NHL subtypes. The project expands previous InterLymph pooled analyses (20, 22, 27, 28, 32, (35) (36) (37) (38) (39) (40) (41) (42) by examining a range of exposures in the same analysis for each NHL subtype, quantitatively assessing differences and commonalities in risk factor associations across a broader range of NHL subtypes, and including new studies that recently joined the consortium. In this article, we describe in detail the design and methods of the project.
Methods

Project Structure and Coordination
The InterLymph NHL Subtypes Project was governed by a Project Coordinating Committee, with representation from each contributing study and InterLymph working group (Immunity & Infection, Lifestyle & Environment, and Pathology). The Committee was led by an interdisciplinary group of epidemiologists (LMM, MSL, JRC), pathologists (DDW, JJT), and biostatisticians (SLS, JNS) who initiated and/or led the project. Additional oversight of the analyses was provided by an analytic working group with biostatisticians from three participating studies (JNS, SLS, YB). Project coordinators corresponded regularly by e-mail and teleconference, and met in-person at four annual InterLymph meetings during 2010-2013. Working groups for each NHL subtype included in the project were formed with representation from participating studies and with other InterLymph members with expertise and interest in that particular subtype. Each group included at least one pathologist, clinician, and biostatistician, in addition to epidemiologists. Communication was facilitated by use of a password-protected web portal for posting study documents and results. Decisions were made by consensus or voting.
Study Population
Studies eligible for inclusion in these pooled analyses fulfilled the following criteria: 1) case-control design, with incident cases of NHL and information on NHL subtype, 2) availability of individual-level data by December 31, 2011, and 3) participation in InterLymph. A total of 20 studies fulfilled these criteria ( Table 1) . As described below, studies were included in specific analyses where cases were available with the subtype of interest and data were collected on the particular risk factor under evaluation. Contributing studies were approved by local ethics review committees, and all participants provided informed consent before interview.
Individuals with a known history of solid organ transplantation or HIV/AIDS were ineligible for most studies; any individual who reported a history of these conditions during patient interviews or via questionnaires was excluded from these pooled analyses. All studies conducted direct interviews with study participants, except Iowa/Minnesota and Italy multicenter, which used proxy respondents for deceased cases. In the six studies that used hospital-or clinic-based controls, analyses included all controls used in the original study, regardless of reason for hospital admission.
NHL Subtype Ascertainment and Harmonization
Eligible cases were diagnosed with incident, histologically confirmed NHL. Most studies had centralized review of pathology reports and diagnostic slides by at least one expert hematopathologist to confirm the NHL diagnoses and assign an NHL subtype, except for the National Cancer Institute-Surveillance, Epidemiology, and End Results Program and Italy multicenter studies, in which cases were diagnosed by local pathologists.
Each participating study's pathology review procedures, rules for NHL subtype classification, and NHL subtype distribution were reviewed by an interdisciplinary team of hematopathologists and epidemiologists. We grouped cases into NHL subtypes according to the WHO classification (2,3) using guidelines from the InterLymph Pathology Working Group (64, 65) . NHL subtypes with more than 100 cases in the pooled dataset were eligible for inclusion in this project.
Because of the potential for risk factors to differ by primary site of disease for certain NHL subtypes (e.g., Sjögren's syndrome and salivary gland marginal zone lymphoma) (22) , we further classified cases according to primary site of NHL for secondary analyses.
In most studies (N = 14), primary site of NHL was recorded if known, irrespective of disease stage. In some NHL subtypes, site is a diagnostic criterion. NHL site was categorized as nodal, extranodal lymphatic (Waldeyer's ring, thymus, or spleen), or extranodal extralymphatic (66) . Specific primary sites (e.g., skin, gastrointestinal tract) also were recorded for further analysis in some NHL subtypes. Leukemias were classified as systemic by definition. Cases with widespread disease or primary site listed as bone marrow, blood, or cerebrospinal fluid, and in which subtype was not sitespecific by definition, also were classified as systemic.
Risk Factor Ascertainment and Harmonization
Each study collected data on putative NHL risk factors in a standardized, structured format by in-person or telephone interviews and/or self-administered questionnaires. In some studies, participants also provided a venous blood sample. Risk factors selected for inclusion in this analysis were the available medical history, family history of hematologic malignancy, lifestyle factors, and occupations with data from at least four studies.
Each study contributed de-identified, individual-level data for the risk factors of interest. Data harmonization was conducted centrally at the Mayo Clinic under the leadership of SLS. Each 0||  0||  0||  0||  0||  6  0 §  3  0  227  UCSF1  1302  509  352  0||  0||  0||  0||  0 §  47  28  0 § 12  0  354  Total  17 471  4667  3530  2440  1052 584  557  374  324  295 154  152  50  3292 * ALL = acute lymphoblastic leukemia; BL = Burkitt lymphoma/leukemia; CLL/SLL = chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma; HCL = hairy cell leukemia; InterLymph = International Lymphoma Epidemiology Consortium; LPL = lymphoplasmacytic lymphoma/Waldenström macroglobulinemia; MCL = mantle cell lymphoma; MF/SS = mycosis fungoides/Sézary syndrome; MZL = marginal zone lymphoma; NCI-SEER = National Cancer Institute-Surveillance, Epidemiology, and End Results Program; NHL = non-Hodgkin lymphoma; NOS = not otherwise specified; PTCL = peripheral T-cell lymphoma; SCALE = Scandinavian Lymphoma Etiology Study; UCSF = University of California, San Francisco; WHO = World Health Organization. † We grouped cases into NHL subtypes according to the WHO classification (2,3) using guidelines from the InterLymph Pathology Working Group (64, 65) . NHL subtypes with more than 100 cases in the pooled dataset were eligible for inclusion in this project. "Other" includes subtypes with less than 100 cases: extranodal natural killer/Tcell lymphoma-nasal type (N = 29), prolymphocytic leukemia (N = 11), T-cell large granular lymphocytic leukemia (N = 8), and adult T-cell leukemia/lymphoma (N = 2). NOS represents poorly specified subtypes (N = 3292). The higher proportion of NOS cases from the Working Formulation studies is due to low correspondence between certain Working Formulation and WHO subtypes (64) . NHL subtypes from the British Columbia, United Kingdom, Engela, and UCSF2 studies were classified using the International Classification of Diseases for Oncology, third edition (70) , and from the NCI-SEER study using the second edition (71), allowing for translation to the WHO classification. ‡ Included SLL but not CLL based on original study eligibility criteria. § NHL subtype excluded based on original study eligibility criteria.
|| NHL subtypes were classified according to the Working Formulation with varying levels of additional pathology data, and certain subtypes could not be distinguished reliably. ¶ The three most common NHL subtypes were excluded from this recently completed study, pending publication of individual study results. exposure variable was harmonized individually and data were then reviewed for consistency among related exposure variables. A small subcommittee reviewed harmonization rules for each exposure, ensured consistency with previously published InterLymph pooled analyses, and advised the analytic approaches for that exposure.
Statistical Analysis
We defined a single analytical plan and applied it to each of the 11 NHL subtypes, with all analyses conducted centrally at the National Cancer Institute under the leadership of JNS and LMM. Here, we describe this plan in terms of a generic NHL subtype. Each analysis defined individuals with a specific NHL subtype as cases, individuals without any type of NHL as controls, and excluded cases with NHL subtypes other than the one of interest. For analyses of a particular subtype, we only included controls from studies that also contributed cases of that subtype. Analyses were conducted using SAS software, version 9.2 (SAS Institute, Inc, Cary, NC).
We examined the relationship between case/control status and each exposure variable individually using unconditional logistic regression models adjusted for age (<30, 30-39, 40-49, 50-59, 60-69, 70-79, ≥80 years), race/ethnicity (white, black, Asian, Hispanic, or other/missing), sex, and study. Confidence intervals (CIs) for the odds ratios (ORs) were estimated by asymptotic theory for maximum likelihood estimation. Statistical significance of each relationship was evaluated by a likelihood ratio test, comparing models with and without the exposure variable of interest, with P values less than .05 identifying putatively influential factors. We excluded individuals who had missing data for the exposure variable of interest, and we excluded both cases and controls from studies where only a single category of the exposure variable of interest was represented (e.g., no cases and no controls reported history of a particular autoimmune condition).
To evaluate effect heterogeneity among the studies included in each analysis, we performed a separate logistic regression within 
Atopy (allergy, asthma, hay fever, or eczema) 
Risk factor Analytic variables Notes
Family history of hematologic malignancy (37) • • Seropositivity • Serum antibodies to hepatitis C virus were evaluated using a thirdgeneration ELISA (76). Peptic ulcer
• Any history of peptic ulcer • Self-reported history of gastric ulcer (three studies), peptic ulcer (seven studies), or any ulcer (one study). Atopy (40) • Any atopic condition • Any allergy • Food allergy • Asthma • Hayfever • Eczema
• Self-reported history of atopic conditions occurring before diagnosis/ interview, including allergy (12 studies), asthma (18 studies), hayfever (15 studies), and eczema (16 studies).
• Any allergy included plant, food, animal, dust, insect, or mold.
• Sensitivity analyses were performed by excluding cases and controls with atopic conditions diagnosed within 2 y of NHL diagnosis/interview. • Analyses considered date of OC use initiation due to substantial changes in OC formulations.
• Age at initiation of HRT use was used as a proxy for premenopausal versus postmenopausal initiation.
• Mean correlation among variables = 0.25. ( ( /( )) /( ) and k n = − ' 1. In the absence of heterogeneity, H is expected to equal 1. Statistically significant heterogeneity among studies was identified by 95% CI for H that excluded 1. If a category within a particular study included no cases, suggesting that the disease risk was 0 or the log(OR) = −∞, we set the log(OR) to −2 and estimated the standard deviation by rerunning the logistic regression with an additional case added into that category.
We then examined the relationship between case/control status and each putative risk factor considering possible effect modification and accounting for other potential confounders. To consider possible effect modification, we repeated the above logistic regression analyses, but now stratified individuals by age, sex, race/ethnicity, region (North America, Northern Europe, Southern Europe, and Australia), study, study design (i.e., population-based versus. hospital-or clinic-based studies), or putative risk factors identified in the analysis. Forest plots illustrated the results from the stratified analyses to identify possible effect modifiers for each exposure variable. To account for potential confounding, we conducted two analyses. First, we evaluated the risk estimate for each putative risk factor in a series of models that adjusted for one other putative risk factor at a time (as well as age, race/ethnicity, sex, and study). Second, we conducted a single logistic regression analysis including all putative risk factors, age, sex, race, and study, this time including a separate missing category for each variable to ensure that the whole study population was included in the analysis (i.e., not excluded due to missing data). Note, however, that the likelihood ratio P values for a putative risk factor excluded the effect of this newly created missing category. Finally, we conducted a forward step-wise logistic regression with all putative risk factors, adjusting for age, sex, race/ethnicity, and study.
In most of the original studies, controls were frequency-matched to cases by age and sex. However, because some studies included cases with Hodgkin lymphoma, myeloma, leukemia, and/or softtissue sarcoma in addition to NHL (Table 1) , each analysis included only a subset of cases causing the matching to be broken. Therefore, as a sensitivity analysis, we repeated the analyses described above using a subset of controls that were frequency-matched by age and sex to cases with that NHL subtype. The results from these sensitivity analyses were very similar to the results obtained using the full set of controls, thus we retained the full set of controls for our main analyses to increase statistical power.
The power to detect an association between a dichotomous characteristic and NHL subtype depends on the number of available cases, the prevalence of the characteristic, and the strength of the association. To understand the potential types of associations detectable for each subtype, we calculated the power for varying combinations of those three parameters (Figure 1) . The calculations assumed a 1:5 case:control ratio, an α level of 0.05, and that the estimated proportions of exposed cases and controls were normally distributed.
Results
Study Population
Twenty studies from North America (N = 12), Europe (N = 7), and Australia (N = 1) were included in the InterLymph NHL Subtypes Project, representing most of the large-scale case-control studies of NHL conducted over the last three decades in these regions ( Table 1 ). The pooled dataset included a total of 17 471 NHL cases and 23 096 controls. More than 75% of participants were derived from the 14 population-based studies, with the remaining participants from hospital-or clinic-based studies. The pooled study controls were 58% male and 93% non-Hispanic white, and had a median age at interview of 59 years (range 16-98 years); 41% were classified in the lowest tertile of socioeconomic status (Table 2) .
NHL Subtypes
Of the 17 471 NHL cases in the pooled analyses, 11 976 (69%) were derived from studies that classified NHL subtypes according to the WHO classification (2,3) or its closely related predecessor, the Revised European-American Lymphoma classification (68) ( Table 3 ). The remaining 5495 (31%) cases were classified according to the Working Formulation (69) . Among cases originally defined by the WHO classification, 11 023 (92%) were assigned to one of the 11 subtypes included in this project (i.e., with >100 cases), with the remaining cases assigned to a rare (N = 50 total, <1%) or unspecified (N = 900, 8%) NHL subtype. Where the Working Formulation was the original coding scheme, 3106 (57%) cases were assigned to one of the 11 subtypes included in this project, with the remaining 2389 (43%) considered poorly specified because certain Working Formulation subtypes do not reliably correspond to subtypes defined by the WHO (e.g., chronic lymphocytic leukemia/small lymphocytic lymphoma) or were not recognized in the Working Formulation (e.g., marginal zone lymphoma, mantle cell lymphoma) (64) .
Risk Factors
Analyses included risk factors with data from at least four studies (Table 4, Supplementary Table 1) . Details of the harmonization of exposure variables across studies are provided for medical history factors and family history of hematologic malignancy (Table 5) , lifestyle factors (Table 6) , and farming and occupation (Table 7) .
Discussion
The InterLymph NHL Subtypes Project represents the largest and most comprehensive analysis of medical history, lifestyle factors, family history of hematologic malignancy, and occupation with risk for specific NHL subtypes conducted to date. Findings from this project, as described in subsequent articles in this issue (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) , accomplish two of the primary goals of the consortium: investigation of the etiology of specific NHL subtypes and comparison of risk factors, including those of rare prevalence, among NHL • Data were collected and analyzed separately by beverage type (e.g., beer, wine, and liquor) and then summed to evaluate total alcohol consumption (15 studies), or collected only for any alcohol consumption (two studies).
• Alcohol consumption was defined as consumption of alcohol ≥1 time per month on average as an adult.
• Former consumption was defined as stopping drinking within 2 y of diagnosis/interview (eight studies). • Ever smokers were defined as having smoked >100 cigarettes in their lifetime or having smoked regularly (at least 1 cigarette per day) for at least 6 months.
• Former smoking was defined as stopping smoking within 2 y of diagnosis/interview. • Some studies did not collect information on duration of smoking.
• Mean correlation among smoking variables = 0.79. Physical activity
• Recreational physical activity • Data on recreational physical activity were classified as vigorous, moderate, mild, or no regular activity. Personal hair dye use (39) • • For each personal hair dye product used, data were collected on the color, type, age at first use, and frequency and duration of use. • Analyses were performed by calendar year of first use (before versus after 1980) due to substantial changes in hair dye formulations.
• Men were excluded from analysis.
• Mean correlation among hair dye variables = 0.52. Sun exposure (32) • Lifetime total sun exposure (hours/week) • Lifetime recreational sun exposure (h/wk)
• Exposure was reported as recreational (three studies), recreational/nonrecreational (five studies), or total (three studies).
• For studies that asked about sun exposures separately at different time periods (e.g., by decade of life or at certain time points before diagnosis/interview), a composite measure of "lifetime" exposure was computed using time-weighted averages of reported data.
• Correlation between total and recreational sun exposure = 0.73. subtypes to better understand the etiologic heterogeneity within this common hematologic malignancy.
The primary strengths of the project are the large sample size, achieved by pooling data from 20 studies with a total of 17 471 NHL cases and 23 096 controls, and centralized data harmonization and analysis. For less common NHL subtypes, the relatively large sample size enabled the first broad investigation of associations for medical history, lifestyle factors, family history of hematologic malignancy, and occupation, with sufficient statistical power to detect ORs < 2.0 for prevalent exposures (e.g., obesity) and ORs of 2.0-4.0 for rarer exposures (e.g., autoimmune conditions) or exposures ascertained in fewer studies (Figure 1 ). For common NHL subtypes, the large sample size facilitated evaluation of risk factors in multivariate models, allowing for consideration of potential confounding and effect modification among risk factors, with sufficient statistical power to detect ORs < 2.0 even for some rarer exposures.
By centralizing the data harmonization and analysis, we ensured rigorous quality control at all stages of the project and standardized approaches to defining exposures and conducting statistical models, which allowed both pooling and direct comparisons among studies and within subgroups. We also leveraged the vast interdisciplinary expertise of InterLymph collaborators to define and categorize both exposure and outcome variables for analysis.
Despite the strengths noted above, several weaknesses of the project should be taken into consideration when interpreting the results. A key complication of the analysis was the variability of available data on both exposures and outcomes from different studies (Tables 3-4,  Supplementary Table 1) . Although certain exposures (e.g., family history of hematologic malignancy, history of cigarette smoking) were ascertained by nearly all studies, data on other exposures (e.g., reproductive history, personal hair dye use) were collected in fewer than half the studies. Individual studies also had varying eligibility criteria for inclusion of specific NHL subtypes, particularly the inclusion of lymphoid leukemias in some but not all studies.
Another limitation was lack of centralized pathology review of all cases included in the pooled analysis, although nearly all studies individually conducted some form of pathology review by at least one expert hematopathologist to confirm the initial diagnoses and assign NHL subtypes. Insufficient pathology data were available to further subclassify certain histological subtypes, such as diffuse large B-cell lymphoma, which comprises numerous subentities (3) .
Additional limitations of the project are similar to those inherent in pooled analyses of case-control studies with interview-or questionnaire-based (i.e., self-reported) ascertainment of exposures. Examples include potential bias of risk estimates due to biased selection of the study population, differential recall of exposures between cases and controls, and exclusion of cases with the most aggressive disease because studies could have missed cases who had died or were too ill to participate, although rapid case-ascertainment used by most studies should have minimized such effects. Exposure information was not ascertained uniformly in all studies, although centralized harmonization of data enabled us to apply standardized exposure definitions despite differences in questionnaire structure. Analyses were restricted to those exposures for which data were collected in the individual studies. Finally, the studies included in the project were predominantly conducted in non-Hispanic white populations Table 7 . Harmonization of farming and occupational risk factor data for the InterLymph NHL Subtypes Project
Risk factor Analytic variables Notes
Farm exposure • Ever lived on a farm • Ever worked on a farm • Ever lived or worked on a farm
• Self-reported history of working on a farm (six studies) or living or working on a farm (six studies separated a history of living and working, and four studies queried participants in a single question).
• Mean correlation among farming variables (including occupations below) = 0.34. • A detailed work history was captured in eight studies, and an additional two studies collected information on the longest held occupation.
Occupation
• Occupations were coded according to the International Standard Classification of Occupations, Revised Edition 1968 (77).
• Based on literature review, 26 categories of occupations were included in this analysis based on a priori evidence of an association with lymphoid malignancies. Certain subgroups with more specific occupations within these categories (specified in parentheses) also were included based on post hoc evidence of association in a recent pooled analysis.
• Mean correlation among 24 occupations (excluding farming and hairdye) = 0.0.
in Western countries, and thus the results may not be generalizable to individuals in with substantially different exposure prevalences (e.g., hepatitis C virus infection, autoimmune conditions). The InterLymph NHL Subtypes Project demonstrates the benefits of long-term and large-scale international collaboration for advancing etiologic research. Results from the project identify important associations with specific NHL subtypes for some risk factors and shared among multiple NHL subtypes for others (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) . Findings also suggest possible mechanisms of lymphomagenesis and provide clues for prevention with modifiable risk factors. Future research with complementary study designs (e.g., prospective cohort studies) will help confirm associations observed in these case-control data. Additionally, combining our findings with large-scale studies of genetic susceptibility will provide further insight into the interplay of environmental and genetic factors in the etiology of NHL.
